Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 10Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 7Multiple Myeloma 7Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 5Hodgkin Disease 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Hematologic Neoplasms 3Recurrence 2Paraproteinemias 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Congenital Abnormalities 2Burkitt Lymphoma 2Anemia, Aplastic 2Waldenstrom Macroglobulinemia 1Shwachman-Diamond Syndrome 1Sezary Syndrome 1Primary Immunodeficiency Diseases 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

ruxolitinib 1filanesib 1Stem Cell Transplantation 1Melphalan 1Clofarabine 1CPI-0610 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Preleukemia × Alemtuzumab × Clear all
NCT00943592 2014-02-27

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

University of Chicago

Phase 1/2 Completed
82 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡